Drug General Information
Drug ID
D0Z0PR
Former ID
DNC005713
Drug Name
L-006235-1
Drug Type
Small molecular drug
Indication Discovery agent Investigative [527882]
Structure
Download
2D MOL

3D MOL

Formula
C24H30N6O2S
Canonical SMILES
CN1CCN(CC1)C2=NC(=CS2)C3=CC=C(C=C3)C(=O)NC4(CCCCC4)C(=O<br />)NCC#N
InChI
1S/C24H30N6O2S/c1-29-13-15-30(16-14-29)23-27-20(17-33-23)18-5-7-19(8-6-18)21(31)28-24(9-3-2-4-10-24)22(32)26-12-11-25/h5-8,17H,2-4,9-10,12-16H2,1H3,(H,26,32)(H,28,31)
InChIKey
FIVYCSWOCXEWSE-UHFFFAOYSA-N
PubChem Compound ID
Target and Pathway
Target(s) Cathepsin S Target Info Inhibitor [527882]
Cathepsin L Target Info Inhibitor [527882]
Cathepsin B Target Info Inhibitor [527882]
Cathepsin K Target Info Inhibitor [527882]
KEGG Pathway Lysosome
Phagosome
Antigen processing and presentation
Tuberculosishsa04142:Lysosome
Proteoglycans in cancer
Rheumatoid arthritishsa04142:Lysosome
Antigen processing and presentationhsa04142:Lysosome
Osteoclast differentiation
Toll-like receptor signaling pathway
Rheumatoid arthritis
NetPath Pathway Leptin Signaling Pathway
IL2 Signaling PathwayNetPath_16:IL4 Signaling Pathway
TGF_beta_Receptor Signaling PathwayNetPath_11:TCR Signaling Pathway
IL2 Signaling PathwayNetPath_7:TGF_beta_Receptor Signaling Pathway
RANKL Signaling Pathway
IL2 Signaling Pathway
Reactome Endosomal/Vacuolar pathway
Degradation of the extracellular matrix
Trafficking and processing of endosomal TLR
Assembly of collagen fibrils and other multimeric structures
MHC class II antigen presentationR-HSA-1236977:Endosomal/Vacuolar pathway
Collagen degradation
MHC class II antigen presentationR-HSA-1442490:Collagen degradation
Activation of Matrix Metalloproteinases
MHC class II antigen presentation
WikiPathways Class I MHC mediated antigen processing & presentation
Trafficking and processing of endosomal TLRWP2572:Primary Focal Segmental Glomerulosclerosis FSGSWP2018:RANKL/RANK Signaling Pathway
Osteoclast Signaling
References
Ref 527882J Med Chem. 2005 Dec 1;48(24):7535-43.Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivity.
Ref 527882J Med Chem. 2005 Dec 1;48(24):7535-43.Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivity.

If you find any error in data or bug in web service, please kindly report it to Dr. Wang and Dr. Li.